Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

trial was not designed to analyze statistical differences in any of the sub-groups, including diabetic patients.

"The results from XIENCE V represent an important advancement for patients with coronary artery disease," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "As a next generation drug eluting stent, XIENCE V continues to demonstrate longer-term safety and consistently superior efficacy results across the SPIRIT trials with the potential to raise the bar for all DES."

About XIENCE V

The XIENCE V system utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation, and is based upon the highly deliverable and proven MULTI-LINK VISION coronary stent platform.

XIENCE V was launched in Europe and Asia Pacific in 2006. XIENCE V is currently an investigational device in the United States and Japan. Results from the SPIRIT III trial are intended to support U.S. Food and Drug Administration (FDA) approval of the XIENCE V Stent System and Ministry of Health and Welfare approval in Japan. Abbott anticipates receiving XIENCE V U.S. FDA approval in the first half of 2008.

Abbott supplies a private-label version of XIENCE V, called the PROMUS(TM) Everolimus-Eluting Coronary Stent System, to Boston Scientific as part of a distribution agreement established between the two companies last year.

About the SPIRIT Family of Trials

SPIRIT FIRST was a first-in-man study comparing the XIENCE V Everolimus Eluting Coronary Stent System with the MULTI-LINK VISION metallic stent system. SPIRIT FIRST demonstrated positive results with one MACE event at one year and no additional MACE events out to three years. In addition, the number of late stent thromboses in the XIENCE V arm of the SPIRIT FIRST trial was zero out to three years of clinical follow-up.

SPIRIT II is a 300-patient randomized, single-blind, prospective clinical trial evaluating XIE
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today reported financial results ... Global revenue for the Company,s Urgent ® ... new quarterly revenue record, as compared to $3.9 million ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... S.C., Nov. 30 The Eleventh Annual Southeastern BIO Investor ... Hotel in the historic district of Charleston, SC, on December ... Dr. Jeremy M. Stipkala, patent attorneys with Stipkala LLC, will ... companies, investors, scientists, entrepreneurs, and service providers from around the ...
... , MELVILLE, N.Y., Nov. 30 Henry Schein, Inc., ... and services, announced today that Steven Paladino, the Company,s Executive Vice ... 23rd Investor Program on Tuesday, December 1, 2009. The conference ... Henry Schein,s presentation is scheduled to begin at 9:15 a.m. EST ...
Cached Medicine Technology:Henry Schein to Present at the NASDAQ OMX 23rd Investor Program 2
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... A. Adams has,been named president of the Northern ... Kaiser Foundation Hospitals, effective,April 1, announced Bernard J. ... Health Plan Operations. Adams succeeds Mary Ann,Thode, who ... but,will continue to serve as national senior vice ...
... New Breads offer Latest Nutritional Advancements, FORT ... continuing effort,to pioneer the advancement of nutrition in ... 9 Grain with Omega-3 DHA. Active Health is ... United States while 9,Grain with Omega-3 DHA provides ...
... 1, 2008 The Centers,for Medicare & Medicaid ... have released HCAHPS scores that cover patient satisfaction,from ... of a patient,s,hospital experience. Virginia Hospital Center scored ... as the overall rating of the hospital,the likelihood ...
... Visit Local Retailers for Easy One-Stop Registration for All Race ... up and,running and it,s time to sign up for the ... 5K event will be held in Washington, D.C. on,Saturday, June ... the country, including 3,500 breast cancer survivors, will convene,on the ...
... ROCHESTER, Minn., April 1, 2008 Obesity is,more ... person,s risk for,developing high blood pressure, diabetes and ... consuming more calories than you expend,through exercise and ... in every three American adults now considered obese, ...
... in Meth use, PALTO ALTO, Calif., April ... new advertising campaign, including a series of,television ads ... Oscar-nominated director and producer whose works,include "Babel," "21 ... in Montana, are designed to communicate the consequences ...
Cached Medicine News:Health News:Gregory A. Adams Named Northern California Region President of Kaiser Foundation Health Plan and Hospitals 2Health News:Gregory A. Adams Named Northern California Region President of Kaiser Foundation Health Plan and Hospitals 3Health News:Oroweat Takes Health and Nutrition to the Next Level 2Health News:Virginia Hospital Center Reports HCAHPS Scores 2Health News:Susan G. Komen for the Cure(C) Opens Registration For 19th Annual Susan G. Komen National Race for the Cure(C) 2Health News:Susan G. Komen for the Cure(C) Opens Registration For 19th Annual Susan G. Komen National Race for the Cure(C) 3Health News:Susan G. Komen for the Cure(C) Opens Registration For 19th Annual Susan G. Komen National Race for the Cure(C) 4Health News:Mayo Clinic Proceedings Examines a Possible Link Between Bacteria Found in the Human Digestive System and Obesity 2Health News:Mayo Clinic Proceedings Examines a Possible Link Between Bacteria Found in the Human Digestive System and Obesity 3Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 2Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 3Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 4
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kaye Skin Hook, Single Prong...
Designated most popular model or size....
Medicine Products: